Nurix Therapeutics (NRIX) Assets Average (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Assets Average data on file, last reported at $662.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $662.1 million, up 3.1% year-over-year; the trailing twelve-month figure through Feb 2026 was $662.1 million (up 3.1% YoY), and the FY2025 annual result was $678.7 million, up 32.44% from the prior year.
• Assets Average advanced to $662.1 million in Q1 2026 per NRIX's latest filing, from $605.3 million in the prior quarter.
• Over five years, Assets Average peaked at $662.1 million in Q1 2026 and troughed at $329.4 million in Q3 2023.
• A 5-year average of $474.9 million and a median of $438.0 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2025: Assets Average decreased 24.23% in 2023, then soared 92.2% in 2025.
• A 5-year view of Assets Average shows it stood at $438.0 million in 2022, then slipped by 24.23% to $331.9 million in 2023, then surged by 78.21% to $591.5 million in 2024, then gained by 2.34% to $605.3 million in 2025, then increased by 9.39% to $662.1 million in 2026.
• Business Quant data shows NRIX's Assets Average at $662.1 million in Q1 2026, $605.3 million in Q4 2025, and $557.0 million in Q3 2025.